The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer.
 
Cayce Ben Nawaf
No Relationships to Disclose
 
Bo Peng
No Relationships to Disclose
 
Melissa Andrea Reimers
Honoraria - Society of Urologic Nurses and Associates (SUNA)
Research Funding - Amgen (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst)
 
Cody Weimholt
No Relationships to Disclose
 
Kathryn Slane
No Relationships to Disclose
 
Peter John Oppelt
Speakers' Bureau - Bristol Myers Squibb; Eisai; Merck
 
Jason Frankel
No Relationships to Disclose
 
Robert S. Figenshau
No Relationships to Disclose
 
Eric H Kim
No Relationships to Disclose
 
Gerald L. Andriole
No Relationships to Disclose
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; SOTERIA Precision Medicine; Sutro Biopharma
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Innovent Biologics; Janssen Oncology; Merck; Nutcracker Therapeutics, Inc.; RAPT Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche